Dok-7 Polyclonal Antibody

Rabbit Anti-Dok-7 Polyclonal Antibody

Product Specifications

Background

The docking protein 7 encoded by DOK7 is essential for neuromuscular synaptogenesis. The protein functions in aneural activation of muscle-specific receptor kinase, which is required for postsynaptic differentiation, and in the subsequent clustering of the acetylcholine receptor in myotubes. This protein can also induce autophosphorylation of muscle-specific receptor kinase. Mutations in DOK7 are a cause of familial limb-girdle myasthenia autosomal recessive, which is also known as congenital myasthenic syndrome type 1B. Alternative splicing results in multiple transcript variants.

CAS Number

9007-83-4

Product Name Alternative

DOK7; C4orf25; Protein Dok-7; Downstream of tyrosine kinase 7

Gene ID

285489

Accession Number

Q18PE1

Reactivity

Human, Mouse

Immunogen

Synthesized peptide derived from the N-terminal region of human Dok-7 at AA rangle: 10-90

Clonality

Polyclonal

Tag

Protein Dok-7

Applications

WB, IHC, IF, ELISA

Purification Method

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration

1 mg/ml

Molecular Weight

60kD

Precautions

The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Shipping Conditions

Gel pack with blue ice.

Storage Conditions

Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Notes

Dok-7 Polyclonal Antibody detects endogenous levels of Dok-7 protein.

Observed Molecular Weight

Formulation

Liquid solution

Buffer pH

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Applications Notes

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000; IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:20000; Not yet tested in other applications.